ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "innate immunity"

  • Abstract Number: 1498 • ACR Convergence 2023

    First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

    Giorgio Senaldi1, Aparna Mohan1, Li Zhang1, Jun Tanaka2, Grishma Pandya3, Sindee Grossman3, Sarah Urbina4, Steven Reynolds5 and Alan Hand4, 1Daiichi Sankyo, Basking Ridge, NJ, 2Daiichi Sankyo, Inc., Basking Ridge, NJ, 3Daiichi Sankyo Inc., Basking Ridge, NJ, 4Worldwide Clinical Trials, San Antonio, TX, 5Cenexel, Los Alamitos, CA

    Background/Purpose: Toll-like receptor (TLR)7 is a pattern recognition receptor, whose ligands include nucleic acids and whose activation is part of the pathogenesis of systemic lupus…
  • Abstract Number: 0051 • ACR Convergence 2023

    CD14+CD64+ Classical Monocytes Are the Main Producers of IL-23 at the Enthesis

    Nicole McDermott1, Thomas Macleod1, Ala Altaie1, Liz Straszynski2, Robert Dunsmuir3, Vishal Borse3, Peter Loughenbury3, Davide Simone4, Stevephen Sansom4, Christopher Buckley4 and Dennis McGonagle5, 1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2Leeds Institute of Medical Research at St. James’s, Leeds, United Kingdom, 3Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom, 4Kennedy Institute of Rheumatology, Oxford, United Kingdom, 5Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: IL-23 is a key cytokine involved in diseases such as psoriasis, psoriatic arthritis and spondyloarthropathies (SpA) and inflammatory bowel disease.IL-23 is produced by activated…
  • Abstract Number: 1587 • ACR Convergence 2023

    Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity

    Benjamin Klein, Mack Reynolds, Bin Xu, Mehrnaz Gharaee-Kermani, Amanda Victory, Shannon Loftus, Mary O'Riordan and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Autoimmune photosensitivity is observed in type I Interferon (IFN) mediated diseases such as systemic and cutaneous lupus erythematosus (SLE/CLE) and dermatomyositis. Type I IFN…
  • Abstract Number: 0056 • ACR Convergence 2023

    The Activation of cGAS-STING Pathway in Systemic Lupus Erythematosus

    Jie An1, Stephen Wilson2, Jill Henault3 and Keith Elkon1, 1University of Washington, Seattle, WA, 2Bristol Myers Squibb, Cambridge, MA, 3Bristol Myers Squibb, Acton, MA

    Background/Purpose: The majority of patients with SLE show a striking Type I Interferon (IFN-I) signature in their peripheral blood. Although this signature can be generated…
  • Abstract Number: 1662 • ACR Convergence 2023

    Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency

    Jemy Varghese1, Scott Canna1, Emily Landy2, Laurence Eisenlohr1, Elise Peauroi3, Vinh Dang1, Anastasia Frank-Kamenetskii4 and Jeremy Morrissette5, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, PA, 4CHOP/UPENN, Philadelphia, PA, 5University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) and Macrophage Activation Syndrome (MAS) are associated with highly elevated peripheral blood levels of the inflammasome-activated cytokine IL-18 and…
  • Abstract Number: 0259 • ACR Convergence 2023

    Preliminary Experience with a Novel “Fix” for Deep Epitope and Transcriptional Phenotyping of Fragile Cells from Autoinflammatory Flares

    Hallie Carol1, Emily Landy2 and Scott Canna1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Autoinflammatory diseases (AID) are characterized by inflammation and immunopathology due to primary defects in the innate immune response. Neutrophils (PMN) feature prominently in the…
  • Abstract Number: 1676 • ACR Convergence 2023

    Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology

    Paula David1, Thomas Macleod2, Yu Shi3, Payal Ganguly1, Cedric Duval3, Mark Harland1, Chi Wong1, Benazir Saleem4 and Dennis McGonagle5, 1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, 2University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 3Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, 5Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) patients treated with Janus Kinase inhibitors (JAKi) have reportedly higher venous thromboembolism (VTE) risk and atherosclerotic-related complications including myocardial infarction (1).Although…
  • Abstract Number: 0757 • ACR Convergence 2023

    Identification of 23 Novel COPA Rare Exonic Non-Synonymous Variants and Their Associated Autoimmune and Inflammatory Clinical Phenotypes Among 53,364 Individuals

    Pierre-Antoine Juge1, Gregory McDermott2, Keigo Hayashi2, Jing Cui3, Clémence David-Gabarre4, Marie-Louis Frémond4, Holly Wobma5, Soumya Raychaudhuri2, Elizabeth Karlson2, Philippe Dieudé6 and Jeffrey Sparks7, 1Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Imagine, Paris, France, 5Division of Immunology, Boston Children's Hospital, Boston, MA, 6Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, 7Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: COPA syndrome is a rare, severe monogenic autoinflammatory/autoimmune disorder with variable penetrance, most commonly affecting the lungs and joints. It is caused by dominant…
  • Abstract Number: 1712 • ACR Convergence 2023

    Identification and Functional Characterization of Eight CANDLE/PRAAS Causing Proteasome Variants in Five Unrelated Patients

    Adriana Almeida de Jesus1, Jonas J. Papendorf2, Frederic Ebstein3, Sara Alehashemi4, Daniela Pioto5, Anna Kozlova6, Maria Teresa TErreri7, Anna Shcherbina6, Andre Rastegar8, Marta Rodrigues9, Renan Pereira10, Sophia Park11, Bin Lin12, Kat Uss11, Ana Flavia da Silva Pina5, FLAVIO SZTAJNBOK13, Sofia Torreggiani14, Jennifer Stoddard15, Julie Niemela15, Sergio Rosenzweig15, Adriana Fonseca16, Marietta De Guzman17, Nicole Micheloni5, Melissa Fraga5, Sandro Perazzio18, Raphaela Goldbach-Mansky19 and Elke Krueger2, 1NIAID, NIH, Bethesda, MD, 2Institut für Medizinische Biochemie und Molekularbiologie (IMBM), Universitätsmedizin Greifswald, Greifswald, Germany, 3Nantes Université, Nantes, France, 4NIH/NIAID/TADS, Clarksville, MD, 5Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, 6Center for Pediatric Hematology, Oncology, Immunology, Moscow, Russia, 7UNIFESP, São Paulo, Brazil, 8NIH, Bethesda, MD, 9Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, 10Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 11Translational Autoinflammatory Diseases Section, LCIM, NIAID, NIH, Bethesda, MD, 12Translational Autoinflammatory Diseases Section l LCIM, NIAID, NIH, Bethesda, MD, 13UFRJ/UERJ, São Paulo, Brazil, 14University of Maryland Baltimore, Baltimore, MD, 15Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD, 16Instituto de Puericultura e Pediatria Martagao Gesteira / Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, 17Baylor College of Medicine, Houston, TX, 18Universidade de Sao Paulo (Unifesp); Universidade de São Paulo (USP); Fleury Laboratories, São Paulo, Brazil, 19NIH/NIAID, Potomac, MD

    Background/Purpose: Mutations in genes coding for 20S proteasome subunits or proteasome assembly helpers cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE) or…
  • Abstract Number: 0796 • ACR Convergence 2023

    Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis

    Anders Nguyen1, Agnieszka Lastowska1, Miriam Bollmann1, Symeon Kourmoulakis1, Charlotte E. van der Plas1, Anna-Karin Hultgård Ekwall2, Dietmar M. Zaiss3, Gary S Firestein4 and Mattias N.D Svensson5, 1Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, 3Faculty of Medicine, Department of Immune Medicine, University of Regensburg, Regensburg, Germany, Regensburg, Germany, 4Department of Medicine, University of California San Diego, La Jolla, CA, 5University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Immune-cell mediated activation of joint-lining fibroblast-like synoviocytes (FLS) play a key role in joint inflammation and destruction during Rheumatoid arthritis (RA). Thus, identifying factors…
  • Abstract Number: 1761 • ACR Convergence 2023

    JAK/STAT Inhibition Modifies the Innate Lymphoid Cells 1 Immune Response in Patients with Rheumatoid Arthritis

    Lidia La Barbera1, Marianna Lo Pizzo1, Chiara Rizzo1, Leila Mohammadnezhad1, federica Camarda1, Francesco Ciccia2 and Giuliana Guggino1, 1University of Palermo, Palermo, Italy, 2University of Campania - Luigi Vanvitelli, Naples, Italy

    Background/Purpose: Recent evidence suggests that innate lymphoid cells (ILCs) might be involved in rheumatoid arthritis (RA) pathogenesis and individuals at risk of RA exhibited an…
  • Abstract Number: 0881 • ACR Convergence 2023

    Deficiency of the Pattern-recognition Receptor CD14 Protects Against LPS-induced Inhibition of Osteoclastogenesis in Vitro

    Lance Murphy1, Kevin Burt2, Baofeng Hu3, Vu Nguyen2, Robert Mauck2 and Carla Scanzello2, 1University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Osteoarthritis is associated with bone changes such as subchondral sclerosis, bone marrow lesions, and osteophyte formation (Donel S, 2019). Prior work has demonstrated that…
  • Abstract Number: 2206 • ACR Convergence 2023

    Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis

    Eric Toussirot1, Caroline Laheurte2, Eléonore Gravelin2, Charline Vauchy3, Marc Puyraveau3 and Philippe Saas4, 1University Hospital of Besancon, Besançon, France, 2INSERM UMR1098, plateforme de biomonitoring, EFS Bourgogne-Franche-Comté, Besançon, France, 3INSERM CIC-1431, Besançon, France, 4INSERM UMR1098, EFS Bourgogne-Franche-Comté, Besançon, France

    Background/Purpose: MAIT (mucosal associated invariant T) cells are involved in mucosa defense against bacteria. This cellular subset is characterized by a semi-invariant αβ TCR and…
  • Abstract Number: 0888 • ACR Convergence 2023

    Functionally Selective Immunomodulator Shows Robust Efficacy in Spontaneous Lupus Mouse Model

    Helene ASNAGLI1, Simon TESSIER1, Martyn FOSTER2, Sofie DENIES3, Eef HOEBEN4, Joël CROUZET1 and Annegret VAN DER AA1, 1Ermium Therapeutics, Paris, France, 2Experimental Pathology Consultancy, Benfleet, United Kingdom, 3SD Analytics, Bellem, Belgium, 42-Bridge, Zoersel, Belgium

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. Type 1…
  • Abstract Number: 2407 • ACR Convergence 2023

    Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis

    Shozo Ohtsuki1, Chenyao Wang2, Ryu Watanabe3, Hui Zhang3, Mitsuhiro Akiyama3, Kenneth Warrington4, Gerald J. Berry3, Jorg Goronzy4 and Cornelia M. Weyand5, 1Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, 2Mayo Clinic College of Medicine and Science, Rochester, MN, 3Stanford University School of Medicine, Stanford, CA, 4Mayo Clinic, Rochester, MN, 5Mayo Clinic School of Medicine and Stanford University, Rochester, MN

    Background/Purpose: Giant cell arteritis (GCA) is a medium and large vessel vasculitis with pathognomonic granulomatous infiltrates in the vessel wall. During the early stages of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology